SCHEMBL2899790

SCHEMBL2899790

OC(c1ccccc1)c1ccc(Br)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA9 Q16790 3/20 0.41
CA12 O43570 1/20 0.41
CA14 Q9ULX7 1/20 0.41
SLC6A4 P31645 6/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.37
SLC6A2 P23975 5/20 0.36
SLC6A3 Q01959 5/20 0.36
CYP3A4 P08684 4/20 0.36
CYP2D6 P10635 4/20 0.36
KCNH2 Q12809 4/20 0.36
PTGS1 P23219 3/20 0.35
MEN1 O00255 2/20 0.35
PTGS2 P35354 2/20 0.35
KMT2A Q03164 2/20 0.35
FABP2 P12104 1/20 0.35
TSHR P16473 1/20 0.35
AKR1C4 P17516 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17235867 0.87 NR3C1 (0.42) KCNH2KMT2AKIF11
SCHEMBL17235718 0.86 HDAC4 (0.44) CA1CA2CA9SLC6A4SLC6A2
SCHEMBL6950343 0.85 CA1 (0.41) CA1CA2CA9CA12CA14
SCHEMBL7980329 0.84 NPC1 (0.39) TSHRHIF1A
SCHEMBL231190 0.82 CES2 (0.46) CA1CA2CA9CA12CA14
SCHEMBL7678466 0.80 SMN1; SMN2 (0.56) SLC6A4SMN1; SMN2L3MBTL1SLC6A2SLC6A3
SCHEMBL28999627 0.78 SLC6A4 (0.43) SLC6A4SMN1; SMN2SLC6A2SLC6A3CYP3A4
SCHEMBL17894209 0.77 GRIN2B (0.41) SLC6A4
SCHEMBL15532524 0.77 MAPT (0.46) CA1CA2CA9CA12CA14
SCHEMBL7677713 0.77 SLC6A3 (0.39) SLC6A4SLC6A2SLC6A3CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968577-B2 Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2011-06-28 US disclosed
US-20100063051-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2010-03-11 US disclosed
EP-2089355-A2 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF- KAPPA B ACTIVITY AND USE THEREOF Brystol-Myers Squibb Company (US) 2009-08-19 EP disclosed
WO-2008057862-A2 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063051-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF NFRKB, NFKB2, NFKBIA CA1 2942/4885CA2 1675/4885CA9 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.